ypertrophic cardiomyopathy (HCM) is a genetic cardiac disease characterized by cardiac hypertrophy and increased frequency of premature death. However, mutations in the known contractile protein genes are confirmed in, at most, one-third of cases. 1 Recent molecular studies of HCM patients without sarcomeric protein mutations have revealed other genetic causes of cardiac hypertrophy; for example, a metabolic cardiomyopathy because of accumulation of glycogen, thereby leading to severe left ventricular hypertrophy (LVH). 2 Danon disease is an X-linked dominant multisystem disorder that includes HCM with skeletal myopathy, and affected patients have mutations in the gene encoding the lysosome-associated membrane protein-2 (LAMP-2). 3 Affected males typically develop cardiac symptoms before the age of 20 years, whereas most affected women develop cardiomyopathy in adulthood. 4 To date, more than 20 mutations in LAMP2 have been identified, 2, 3, 5, [6] [7] [8] [9] [10] [11] [12] [13] with most resulting in loss of a functional protein. Mice lacking LAMP-2 show similar features to patients, including cardiac hypertrophy and dysfunction. 14, 15 We report a novel LAMP2 mutation in members of a family with Danon disease, who had been diagnosed as having familial HCM.
cal examination revealed mild skeletal myopathy. Electrocardiogram (ECG) showed bizarre QRS waves, widening of the QRS complex and ST changes (Fig 2) . No significant premature ventricular contractions were observed on 24-h Holter monitoring. Echocardiography revealed marked LVH and progressive LV dilatation (Fig 3) , a finding compatible with the dilated phase of HCM. The combined characteristics of HCM and myopathy led us to investigate Danon disease as the underlying etiology. Skeletal muscle biopsy showed mild variation in fiber size (Fig 4A) and small vacuoles were seen in several fibers, which appeared as basophilic granules rather than vacuoles in the hematoxylin-eosin preparation (Fig 4B) . Acetylcholine and nonspecific esterase activities were associated with the vacuolar membranes ( Figs 4C,D) . These findings supported the diagnosis of Danon disease. Retinal lesion, which is also reported to be a feature of Danon disease, 16 was not observed in the proband. His mother and 2 sisters were also diagnosed with cardiac disease (Fig 1) . His mother died at the age of 43 years from advanced heart failure, 4 years after the onset of dilated cardiomyopathy. His elder sister had abnormal ECGs and mild LVH on echocardiography, and the younger sister had electrocardiographic abnormalities suggestive of Wolff-Parkinson-White syndrome, and LVH on echocardiography. No significant premature ventricular contractions were observed on 24-h Holter monitoring in either sister.
Genetic studies were carried out after informed consent was given by all participating patients, as approved by the institutional review board. In the probands, a hemizygous c.573delA variant was identified in exon 5 of LAMP2 (Fig 5) . This deletion results in a frameshift and a premature stop codon (p.D192TfsX49). Both of his sisters were heterozygous for this deletion (Fig 5) , but his father did not carry the mutation. DNA was not available from their deceased mother, but as this is an X-linked gene it is likely that the mother was a carrier.
Discussion
Danon disease is an X-linked dominant multisystem disorder that includes HCM with skeletal myopathy. The patients have mutations in the gene encoding LAMP-2, which is a principal protein of the lysosomal membrane. 3 It has been suggested that the lysosomal membrane is responsible for transport of degradation products to the cytoplasm and regulation of fusion events between lysosomes them- selves and other organelles. 17 Accumulation of autophagic vacuoles has been documented in the cardioskeletal muscles of both patients with Danon disease and in LAMP-2-deficient mice. 3, 14 Thus, LAMP-2 could have a pivotal role in the degradation of autophagosomes within the lysosomal compartment.
LAMP2 is located on chromosome Xq24-q25. It consists of 9 exons in humans, comprising a large luminal domain encoded by exons 1-8 and 2 small transmembrane and cytoplasmic domains encoded by exon 9. To date, at least 27 different mutations leading to LAMP-2 deficiency have been identified in unrelated cases with similar clinical fea- tures (Table 1) . The novel mutation identified in this family is encoded in exon 5 and leads to premature truncation of LAMP-2 with abolition of the transmembrane domain, and thus can lead to an accumulation of autophagic vacuoles mainly in cardiac and skeletal muscle cells.
The prognosis for patients with Danon disease is poor, especially males. 4 In females, signs of heart failure could emerge after 40 years. These findings are compatible with the clinical course of the family presented here. In the proband, signs of heart failure were not evident before 17 years of age, but emerged at 18 years. His mother suffered heart failure at 39 years and died at 43 years. Thus, patients with Danon disease need to be followed closely and cardiac transplantation is the treatment of choice.
Functional analysis of the mutation found in the present family has not been performed, but frameshift mutations are likely to lead to the absence of functional protein (males) or haplo-insufficiency (females), as previously demonstrated. [2] [3] [4] [5] 
